Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 182 results.
LastUpdate Updated on 17/11/2026 [08:29:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Results 25 to 50 of 182 nextPage  

METHODS AND SYSTEM FOR OPTOGENETIC STIMULATION OF ADIPOCYTES

Publication No.:  US20260284229A1 24/09/2026
Applicant: 
MAINEHEALTH [US]
MaineHealth
US_20260284229_A1

Absstract of: US20260284229A1

Provided herein are, inter alia, methods, compositions, and kits for inducing thermogenesis in adipocyte populations. Also included are methods and compositions for increasing thermogenesis in adipocyte populations (e.g., brown/beige/white adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.

ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR BETA-GAMMA AGONISTS

Publication No.:  US20260284145A1 24/09/2026
Applicant: 
SOTIO BIOTECH INC [US]
SOTIO BIOTECH AG [CH]
Sotio Biotech Inc.
Sotio Biotech AG
US_20260284145_A1

Absstract of: US20260284145A1

0000 A combined therapy for treating cancer in a subject, comprising an immune cell population and an Interleukin-2/Inter-leukin-15 receptor beta gamma (IL-2/IL-15Rβγ) agonist. The immune cell population comprises genetically engineered immune cells expressing or overexpressing a metabolism-regulating polypeptide, which may (a) improves glucose uptake activity; (b) modulates the Krebs cycle; (c) enhances lactate concentration; and/or (d) diverts or redirects glucose metabolites out of a glycolysis pathway.

CELL THERAPIES FOR TYPE 1 DIABETES

Publication No.:  US20260285937A1 24/09/2026
Applicant: 
ABATA THERAPEUTICS INC [US]
Abata Therapeutics, Inc.
US_20260285937_A1

Absstract of: US20260285937A1

0000 The present disclosure is directed to T cell receptors targeting GAD65 and isolated cell populations comprising regulatory T cells exogenously expressing said TCRs used to treat Type 1 Diabetes.

TCR WITH HIGH AFFINITY AND SPECIFICITY SPECIFIC FOR PREPROINSULIN PEPTIDE ALWGPDPAAA BOUND TO HLA-A2*02

Publication No.:  US20260285984A1 24/09/2026
Applicant: 
IMMUNOCORE LTD [GB]
IMMUNOCORE LIMITED
US_20260285984_A1

Absstract of: US20260285984A1

The present invention relates to binding molecules comprising a peptide-major histocompatibility complex (pMHC)-binding domain which binds to a ALWGPDPAAA (SEQ ID NO: 1) peptide (derived from human pre-pro insulin (PPI) protein) presented as a peptide-HLA-A*02 complex. Said binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The binding molecules of the invention have high affinity and high specificity for the ALWGPDPAAA (SEQ ID NO: 1)-HLA-A*02 complex. The binding molecules may further comprise an immune suppressor and/or a half-life extending domain. Such binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as diabetes.

KEY TARGETS FOR TRANSGENE-FREE GENOME EDITING TO GENERATE HLB RESISTANT/TOLERANT CITRUS VARIETIES

Publication No.:  WO2026198957A1 24/09/2026
Applicant: 
UNIV OF FLORIDA RESEARCH FOUNDATION INCORPORATED [US]
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
WO_2026198957_A1

Absstract of: WO2026198957A1

Citrus huanglongbing (HLB) caused by 'Candidatus Liberibacter asiaticus' (CLas) is the most devastating citrus disease worldwide. With CLas infection, RNA-seq analyses were performed on HLB-susceptible Valencia sweet orange and HLB-tolerant Sugar Belle mandarin in winter, spring, summer, and fall. CLas infection stimulates the expression of oxidative 5 stress- and cell death/survival related genes. Such genes were selected as gene editing targets, and crRNA and gRNA sequences were determined for transgene-free genome editing of the target genes to generate HLB-resistant/tolerant citrus varieties.

ADIPOCYTE GROWTH INHIBITOR

Publication No.:  US20260283977A1 24/09/2026
Applicant: 
WATANABE OYSTER LABORATORY CO LTD [JP]
WATANABE OYSTER LABORATORY CO., LTD.
US_20260283977_A1

Absstract of: US20260283977A1

ProblemThe present invention provides a useful treatment tool for obesity-related adipogenesis using DHMBA. DHMBA-containing culture suppresses the growth of 3T3-L1 preadipocytes in vitro, leading to a reduction in the number of cells. In an adipocyte differentiation process, culture in the presence of DHMBA suppresses adipogenesis in the process of differentiation of 3T3-L1 preadipocytes into adipocytes through the regulation of various signaling processes associated with insulin signaling.SolutionThe present invention includes 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient and has an inhibitory action on 3T3-L1 preadipocyte growth.

SYSTEM AND METHOD FOR INFUSION SET DISLODGEMENT DETECTION

Publication No.:  US20260284326A1 24/09/2026
Applicant: 
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc.
US_20260284326_A1

Absstract of: US20260284326A1

A portable insulin pump can utilize readings from a sensor incorporated into an infusion set used with the pump to deliver insulin to a patient to determine if the infusion set is or is likely to become dislodged from the patient. Readings from the sensor that are inconsistent with expected readings or a range of expected readings can indicate that the infusion set has become dislodged from the patient.

SYSTEMS AND METHODS FOR MONITORING AND TREATING DIABETIC FOOT ULCERS

Publication No.:  US20260283539A1 24/09/2026
Applicant: 
T J SMITH AND NEPHEW LTD [GB]
T.J.Smith and Nephew,Limited
US_20260283539_A1

Absstract of: US20260283539A1

0000 In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.

COMPATIBILITY CHECK FOR CONTINUOUS GLUCOSE MONITORING APPLICATION

Publication No.:  EP4809909A2 23/09/2026
Applicant: 
DEXCOM INC [US]
DexCom, Inc.
EP_4809909_PA

Absstract of: EP4809909A2

0001 Disclosed are systems, methods, and articles for determining compatibility of a mobile application and operating system on a mobile device. In some aspects, a method includes receiving one or more data values from a mobile device having a mobile medical software application installed thereon, the data value(s) characterizing a version of the software application, a version of an operating system installed on the mobile device, and one or more attributes of the mobile device; determining whether the mobile medical software application is compatible with the operating system by at least comparing the received data value(s) to one or more test values in a configuration file; and sending a message to the mobile device based on the determining, the message causing the software application to operate in one or more of a normal mode, a safe mode, and a non-operational mode.

WIRELESS GLUCOSE MONITORING SYSTEM WITH REPLACEABLE TRANSMITTER PATCH

Publication No.:  EP4808429A1 23/09/2026
Applicant: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
WO_2025106281_A1

Absstract of: WO2025106281A1

Sensor systems are provided that include (i) a sensor configured to obtain sensor data indicative of an analyte level of a user's body, (ii) a first transmitter patch configured in size and shape to overlay the sensor during a first time period of use, (iii) a second transmitter patch configured in size and shape to overlay the sensor during a second time period of use. First sensor data is transmitted from the sensor to the first transmitter patch corresponding to the first time period and second sensor data is transmitted from the sensor to the second transmitter patch corresponding to the second time period. The first transmitter patch can be replaced by the second transmitter patch without removing the sensor.

NETWORK TOPOLOGY FOR INSULIN PUMP SYSTEMS

Publication No.:  EP4811834A2 23/09/2026
Applicant: 
INSULET CORP [US]
Insulet Corporation
EP_4811834_PA

Absstract of: EP4811834A2

In one implementation, an insulin delivery system using an on-body network includes an insulin delivery device that is adapted to administer dosages of insulin to a patient; a controller that is adapted to control operation of the insulin delivery device, to establish a first network connection in which the controller acts in a central role, and to establish a second network connection in which the controller acts in a peripheral role; one or more peripheral devices that are adapted to generate patient data related to blood glucose levels and to transmit the patient data wirelessly over the first network connection, the peripheral devices acting in a peripheral role over the first network connection; and a mobile application installed on a mobile computing device that is programmed to communicate with the controller over the second network connection, the mobile application communicating in a central role over the second network connection.

CONTINUOUS BLOOD SUGAR MEASURING DEVICE

Publication No.:  EP4809921A2 23/09/2026
Applicant: 
I SENS INC [KR]
i-Sens, Inc.
EP_4809921_PA

Absstract of: EP4809921A2

0001 The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.

Stabilisation medium for extending temporal viability of human semen

Publication No.:  GB2704849A 23/09/2026
Applicant: 
SYED BASIM SAROOSH ZAIDI [GB]
ASHWIN RAMACHANDRAN [AU]
ABDUL SYED [AU]
Syed Basim Saroosh Zaidi
Ashwin Ramachandran
Abdul Syed
US_20250275531_PA

Absstract of: GB2704849A

A stabilization medium (optionally having a pH between 7.2-8) for extending temporal viability of human semen for up to a predetermined time period when mixed therewith and maintained within a predetermined temperature range, comprising: one or more pH buffer agents (optionally comprising MOPS or HEPES in a concentration range of 10.0-25.0 mmol); one or more inorganic salts (optionally selected from sodium chloride, potassium chloride, magnesium sulfate heptahydrate, sodium phosphate dihydrate, sodium bicarbonate and calcium chloride dihydrate); one or more organic compounds (optionally selected from glucose, sodium lactate (L-isomer), sodium pyruvate and taurine); and one or more amino acids with antioxidant properties (optionally selected from alanine, aspartate, asparagine, glutamate, alanyl-glutamine, glycine, proline and serine). The stabilization medium may further comprise at least one of: one or more antioxidants (selected from a group comprising acetyl-L-carnitine, alpha-lipoic acid and N-acetyl-L-cysteine); one or more pH-altering compounds (selected from a group comprising sodium dihydrogen phosphate dihydrate, magnesium sulfate heptahydrate, calcium chloride dihydrate, sodium lactate (L-isomer) and sodium pyruvate); one or more antibiotics and chelating agents. The predetermined time period may be up to 72 hours and the predetermined temperature range may be 36.1-37.2 degrees Celsius. Figure 2

WIRELESS GLUCOSE MONITORING SYSTEM WITH DYNAMIC COMMUNICATION MANAGEMENT

Publication No.:  EP4808428A1 23/09/2026
Applicant: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.
WO_2025106280_PA

Absstract of: WO2025106280A1

Techniques are provided for dynamically managing wireless communications of glucose monitoring systems. The systems dynamically adjust the communication session intervals based on various dynamic conditions. Some systems are also configured with an antenna positioned on an opposing side of a chip from other sensor electronics and/or outside of an encasing of potting material to enhance the signaling functionality of the antenna.

PERSONALIZED CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM

Publication No.:  EP4810079A1 23/09/2026
Applicant: 
MEDTRUM TECH INC [CN]
Medtrum Technologies Inc.
EP_4810079_PA

Absstract of: EP4810079A1

0001 The invention discloses a personalized closed-loop artificial pancreas system, comprising: a detection mechanism, an infusion mechanism, and a program mechanism, at least based on the blood glucose value detected by the detection mechanism, the program mechanism generates an insulin infusion instruction and controls the infusion mechanism to perform the infusion, the program mechanism comprises a user interface, and in response to an input from the patient, the program mechanism performs a corresponding meal mode function, the meal mode comprises a high carbohydrate mode and a normal carbohydrate mode. Based on the patient's input, the program mechanism executes the functions of high carbohydrate mode or normal carbohydrate mode, which can be suitable for people with different carbohydrate consumption habits, improve the adaptability of closed-loop artificial pancreas to different populations, and enable people with different carbohydrate consumption habits to maintain satisfactory blood glucose control effects.

Insulin needle shell with double cotton cavities

Publication No.:  CN224777217U 22/09/2026
Applicant: 
FIRST AFFILIATED HOSPITAL WENZHOU MEDICAL UNIV
\u6E29\u5DDE\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u7B2C\u4E00\u533B\u9662
CN_224777217_U

Absstract of: CN224777217U

An insulin needle head shell with double cotton cavities is characterized in that an insulin needle head cavity is formed in the shell, one end of the insulin needle head cavity is closed, the other end of the insulin needle head cavity is covered with a first waterproof tearable film, the inner side of the first waterproof tearable film covers the other end of the insulin needle head cavity, and a second waterproof tearable film is arranged on the outer side of the first waterproof tearable film. The second waterproof tearable film forms a disinfection cotton piece cavity on the outer side of the first waterproof tearable film, a second waterproof tearable film tearable end is arranged on the outer side of the second waterproof tearable film, and the second waterproof tearable film covers the first waterproof tearable film tearable end; a dry cotton piece cavity with an outward opening is formed in the end wall of one end of the insulin needle head cavity, and a sealing piece is arranged on the opening of the dry cotton piece cavity. The portable insulin syringe needle has the advantages that the portable insulin syringe needle is portable and integrated with the insulin syringe needle shell and can be conveniently taken during injection; 2, the insulin needle head cavity can be torn only after the disinfection cotton piece cavity is torn, so that the disinfection cotton piece is firstly used; thirdly, the arrangement of the dry cotton sheet is convenient to press; and fourt

Auxiliary device for insulin subcutaneous injection

Publication No.:  CN224777218U 22/09/2026
Applicant: 
ZHUHAI HIGH NEW TECH INDUSTRIAL DEVELOPMENT ZONE JINDING COMMUNITY HEALTH SERVICE CENTER
\u73E0\u6D77\u9AD8\u65B0\u6280\u672F\u4EA7\u4E1A\u5F00\u53D1\u533A\u91D1\u9F0E\u793E\u533A\u536B\u751F\u670D\u52A1\u4E2D\u5FC3
CN_224777218_U

Absstract of: CN224777218U

An auxiliary device for insulin subcutaneous injection comprises a plurality of fixing plates hinged to one another, extrusion anti-skid protruding strips are arranged on the inner sides of the fixing plates, external thread fixing cylinders are arranged on the outer sides of the fixing plates, adjusting plates are installed in the external thread fixing cylinders in a sliding mode, and protruding plates are arranged on the two sides of the adjusting plates and penetrate through notch grooves of the external thread fixing cylinders. The surface of the external thread fixing cylinder is in threaded connection with an internal thread sleeve, the inner wall of the internal thread sleeve is provided with a concave ring matched with the protruding plate, the inner wall of the external thread fixing cylinder is provided with scale values used for indicating the injection depth, one side of the fixing plate is provided with a butt-joint groove, the other side of the fixing plate is provided with a butt-joint protruding strip, and the end of the butt-joint protruding strip is provided with a fixing bolt, a mounting hole, a sliding hole and a positioning bolt. A spring is arranged in the mounting hole, and a hook surface magic tape and a loop surface magic tape are arranged at the outer end of the fixing plate; according to the insulin injection device, effective dispersing and positioning of injection parts can be achieved, meanwhile, accurate control over the injection depth is achi

Injection amount selection mechanism convenient for blind person to use insulin pen and insulin pen

Publication No.:  CN224777209U 22/09/2026
Applicant: 
SHANGHAI EIGHTH PEOPLE HOSPITAL
\u4E0A\u6D77\u5E02\u7B2C\u516B\u4EBA\u6C11\u533B\u9662
CN_224777209_U

Absstract of: CN224777209U

The utility model provides an insulin pen and an injection amount selecting mechanism convenient for blind people to use, the injection amount selecting mechanism is used for being installed on the insulin pen, the insulin pen comprises a dose selecting knob, the injection amount selecting mechanism comprises an inner sleeve and an outer sleeve, the inner sleeve is arranged in the outer sleeve, and the outer sleeve is arranged in the outer sleeve. The inner sleeve is arranged to rotate relative to the outer sleeve; the inner sleeve is used for being arranged on a dose selection knob of the insulin pen in a sleeving mode and keeping relatively fixed with the dose selection knob in the circumferential direction, a clamping part is arranged at one end of the outer sleeve, and the clamping part is used for being clamped on an insulin shell so that the outer sleeve and the insulin shell can keep relatively fixed; digital braille scales are arranged on the peripheral face of one end, far away from the clamping part, of the outer sleeve, and protruding indication marks are arranged at the same end of the inner sleeve and the digital braille scales. The injection amount selecting mechanism is simple in structure, convenient to operate, convenient for blind patients to independently use the insulin pen and select the insulin dosage, and capable of being repeatedly used, so that the use cost is reduced.

SURVIVOR T CELLS, SURVIVOR T CELL POPULATION, AND PHARMACEUTICAL COMPOSITION

Publication No.:  CA3317451A1 21/09/2026
Applicant: 
NAT CANCER CENTER [JP]
ARC THERAPIES INC [JP]
NATIONAL CANCER CENTER
ARC THERAPIES INC.
WO_2025150522_A1

Absstract of: CA3317451A1

The present disclosure provides cells that are competitive with respect to cancer cells, without experiencing starvation or exhaustion, even in glucose-depleted environments. Specifically, the present disclosure provides survivor T cells with enhanced glucose uptake capacity. The T cells are modified so as to express a glucose transporter and/or configured such that the expression of a glucose transporter is enhanced. Also provided are a cell population including such cells, a pharmaceutical composition, and a treatment method.

SYSTEM AND METHOD FOR WIRELESS COMMUNICATION OF GLUCOSE DATA

Publication No.:  CA3319505A1 21/09/2026
Applicant: 
DEXCOM INC [US]
DEXCOM, INC.
US_2018027104_A1

Absstract of: US2018027104A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.

Method and device for monitoring blood glucose and computer readable storage medium

Publication No.:  CN122781535A 18/09/2026
Applicant: 
HUAWEI TECH CO LTD
\u534E\u4E3A\u6280\u672F\u6709\u9650\u516C\u53F8
CN_122781535_PA

Absstract of: CN122781535A

The invention provides a blood glucose monitoring method and device and a computer readable storage medium, the method comprises the steps that first information and second information are determined, the first information is a blood glucose monitoring result corresponding to a first time period, the second information is a target behavior type associated with the first time period, the target behavior type is one of user behavior types, and the first information is a blood glucose monitoring result corresponding to the first time period; the user behavior type comprises one or more of a dining behavior type, a motion behavior type or a sleep behavior type; generating first prompt information according to the first information and the second information, wherein the first prompt information is used for prompting a blood glucose monitoring result associated with the target behavior type. The method can help the user to realize finer and more effective blood glucose management.

Heterotrophic chlorella growth factor as well as preparation method and application thereof

Publication No.:  CN122772795A 18/09/2026
Applicant: 
LAOSHAN NATIONAL LABORATORY
QINGDAO OCEAN SCIENCE AND TECH CENTER
\u5D02\u5C71\u56FD\u5BB6\u5B9E\u9A8C\u5BA4
\u9752\u5C9B\u6D77\u6D0B\u79D1\u6280\u4E2D\u5FC3
CN_122772795_PA

Absstract of: CN122772795A

The invention discloses a heterotrophic chlorella growth factor as well as a preparation method and application thereof, and the technical scheme includes that the preparation method of the heterotrophic chlorella growth factor comprises a chlorella heterotrophic culture step and a heterotrophic chlorella growth factor extraction step. The chlorella heterotrophic culture step comprises the following steps: carrying out heterotrophic culture on chlorella strains by taking glucose as an organic carbon source and nitrate as an inorganic nitrogen source, culturing to a logarithmic end phase to a plateau phase, and then collecting algae; wherein the molar ratio of the carbon element provided by the glucose to the nitrogen element provided by the nitrate is (0.3-3.0): 1. When the culture medium is applied to fish cell culture, the multiplication capacity, the cell viability and the three-dimensional amplification culture performance of fish muscle-derived cells can be maintained or improved while the use amount of fish cell culture serum is reduced; the fish myogenic cell proliferation can be supported in a 1%-6% low-serum system, the PI positive proportion under the low-serum condition can be reduced, the cell activity is improved, and the cell DNA synthesis and proliferation capacity is maintained.

Data processing method and device based on artificial intelligence, computer equipment and medium

Publication No.:  CN122781539A 18/09/2026
Applicant: 
KANGJIAN INFORMATION TECH SHENZHEN CO LTD
\u5EB7\u952E\u4FE1\u606F\u6280\u672F\uFF08\u6DF1\u5733\uFF09\u6709\u9650\u516C\u53F8
CN_122781539_PA

Absstract of: CN122781539A

The invention belongs to the technical field of artificial intelligence, and relates to an artificial intelligence-based data processing method, which comprises the following steps of: acquiring multi-dimensional data which is acquired from a plurality of sources and corresponds to a user; preprocessing the multi-dimensional data to obtain target data; performing feature extraction on the target data to obtain feature data; predicting the feature data based on a blood glucose prediction model to obtain a blood glucose prediction result; generating a corresponding early warning threshold based on the obtained historical blood glucose data of the user; performing data comparison analysis on the blood glucose prediction result and an early warning threshold value to generate a risk early warning result corresponding to the user; and executing early warning reminding processing corresponding to the user based on the risk early warning result. The invention further provides a data processing device based on artificial intelligence, computer equipment and a storage medium. The method can be applied to a blood glucose data analysis scene in the field of medical science and technology, the processing efficiency of blood glucose risk early warning processing is effectively improved, and the accuracy of the generated risk early warning result can be guaranteed.

Needle dismounting device capable of preventing needle stick injury

Publication No.:  CN224762269U 18/09/2026
Applicant: 
AFFILIATED HOSPITAL GUANGDONG MEDICAL UNIV
\u5E7F\u4E1C\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u533B\u9662
CN_224762269_U

Absstract of: CN224762269U

The utility model relates to the technical field of medical instruments, and discloses a needle removing device capable of preventing needle stick injury, which comprises an injection head, a needle removing device and a needle removing device, the clamping mechanism is arranged on the back surface of the injection head; the clamping mechanism comprises a moving block, and the front face of the moving block is attached to the back face of the injection head. According to the needle dismounting device capable of preventing the needle stick injury, the hand of a medical worker is effectively isolated from a needle head, and due to the fact that the medical worker does not make direct contact with the needle head in the whole process, the needle stick injury event caused by bare-handed operation is fundamentally eradicated, the occupational exposure risk of the medical worker is greatly reduced, and the body health of the medical worker is powerfully guaranteed; and in addition, due to the design of the clamping mechanism, most of common insulin pens can be adapted, the application range of the product is greatly expanded, a unified and convenient solution is provided for different user groups, and troubles brought to users due to the compatibility problem of the product are effectively avoided.

Preparation based on adipose-derived stem cells and application thereof

Nº publicación: CN122768214A 18/09/2026

Applicant:

SHANXI PURUIDE BIOLOGICAL TECH CO LTD
\u5C71\u897F\u83E9\u745E\u5FB7\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8

CN_122768214_PA

Absstract of: CN122768214A

The invention relates to a preparation based on adipose-derived stem cells and application thereof, and belongs to the technical field of medicines. The preparation has a three-layer structure of a core layer, a drug loading layer and a sustained release layer, wherein the core layer is an integrated compound formed by double covalent cross-linking of Chinese wolfberry derived carbon dots and L-arginine derived carbon dots; the medicine carrying layer is a vesicle compound formed by compounding adipose-derived stem cell exosome lipid hybrid and cortex acanthopanacis nano vesicles; and the slow-release layer is a natural polysaccharide carrier such as chitosan, sodium alginate or pectin. According to the preparation, through the synergistic effect of three layers, continuous and stable release of active ingredients is achieved, active oxygen is remarkably removed, expression of inflammatory factors is inhibited, and wound surface cell proliferation, migration and angiogenesis are promoted. Animal experiments show that the preparation can significantly accelerate wound healing of diabetic feet and improve healing quality. The invention provides a novel efficient and safe biomedical preparation for diabetic foot and anti-inflammatory and anti-oxidation treatment.

traducir